Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How would you approach management of an elderly patient with known mantle cell lymphoma and new diagnosis of cryoglobulinemic vasculitis with mild skin involvement, fatigue, arthralgias but no other major organ involvement?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
